Emerging targets for glioblastoma stem cell therapy

Journal of Biomedical Research

Volumn 30, Issue 1, 2016, Pages 19-31

  Safa, Ahmad R ^a,b   Saadatzadeh, Mohammad Reza ^a,b   Cohen Gadol, Aaron A ^b   Pollok, Karen E ^a,b   Bijangi Vishehsaraei, Khadijeh ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ALDH1A1; CD133; CD44; Dedifferentiation; Glioblastoma multiforme; SOX2; Stem cells

Indexed keywords

ANTINEOPLASTIC AGENT; CD133 ANTIGEN; HERMES ANTIGEN; MICRORNA; TRANSCRIPTION FACTOR SOX2;

CANCER THERAPY; CELL DEDIFFERENTIATION; DRUG IDENTIFICATION; DRUG REPOSITIONING; EPIGENETICS; GLIOBLASTOMA; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TARGET CELL;

EID: 84958811608     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.30.20150100     Document Type: Review

References (96)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics[J]. CA Cancer J Clin, 2005,55(1):10-30.
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial[J]. Lancet Oncol, 2009,10(5):459-466.
3. Smoll NR, Schaller K, Gautschi OP, et al. Long-term survival of patients with glioblastoma multiforme (GBM)[J]. J Clin Neurosci, 2013,20(5):670-675.
4. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma[J]. N Engl J Med, 2005,352(10):997-1003.
5. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[ J]. N Engl J Med, 2005,352(10):987-996.
6. Greaves M, Maley CC. Clonal evolution in cancer[J]. Nature, 1212,481(7381):306-313.
7. Szerlip NJ, Pedraza A, Chakravarty D, et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response[J]. Proc Natl Acad Sci USA, 2012,109(8):3041-3046.
8. Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma[J]. Cancer Cell, 2011,20(6):810-817.
9. Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics[J]. Proc Natl Acad Sci USA, 2013, 110(10):4009-4014.
10. Singh SK, Hawkins C, Clarke ID. Identification of human brain tumour initiating cells[J]. Nature, 2004,432(7015): 396-401.
11. Singh AK, Arya RK, Maheshwari S, et al. Tumor heterogeneity and cancer stem cell paradigm: Updates in concept, controversies and clinical relevance[J]. Int J Cancer, 2015,136(9):1991-2000.
12. Yan K1, Yang K, Rich JN. The evolving landscape of glioblastoma stem cells[J]. Curr Opin Neurol, 2013,26(6): 701-707.
13. Jackson M, Hassiotou F, Nowak A. Glioblastoma stemlike cells: At the root of tumor recurrence and a therapeutic target[J]. Carcinogenesis, 2015,36(2):177-185.
14. Gao X, McDonald JT, Naidu M, et al. A proposed quantitative index for assessing the potential contribution of reprogramming to cancer stem cell kinetics[J]. Stem Cells Int, 2014,2014: 249309.
15. Safa, AR, Saadatzadeh, MR, Cohen-Gadol, AA, et al. Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs[J]. Genes & Diseases, 2015,2(2):152-1637.
16. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol, 2007,114(2):97-109.
17. Carén H1, Pollard SM, Beck S. The good, the bad and the ugly: epigenetic mechanisms in glioblastoma[J]. Mol Aspects Med, 2013,34(4):849-862.
18. Hamaya K, Doi K, Tanaka T, et al. The determination of glial fibrillary acidic protein for the diagnosis and histogenetic study of central nervous system tumors: a study of 152 cases[J]. Acta Med Okayama, 1985,39(6):453-462.
19. Jacque CM, Vinner C, Kujas M, et al. Determination of glial fibrillary acidic protein (GFAP) in human brain tumors[J]. Neurol Sci, 1978,35(1):147-155.
20. Masui K, Cloughesy TF, Mischel PS. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies[J]. Neuropathol Appl Neurobiol, 2012,38(3):271-291.
21. Kondo Y, Katsushima K, Ohka F, et al. Epigenetic dysregulation in glioma[J]. Cancer Sci, 2014,105(4):363-369.
22. Appin CL, Brat DJ. Molecular genetics of gliomas[J]. Cancer J, 2014,20(1):66-72.
23. Cadieux B1, Ching TT, VandenBerg SR, et al. Genomewide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation[J]. Cancer Res, 2006,66(17):8469-8476.
24. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1[J]. Cancer Cell, 2010,17(1):98-110.
25. Li L, Chakraborty S, Yang CR, et al. An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII[J]. Oncogene, 2014,14(33):4253- 4264.
26. Padfield E, Ellis HP, Kurian KM. Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma[ J]. Front Oncol, 2015,5: 5.
27. Inda MM, Bonavia R, Mukasa A, et al. Tumor heterogeneity is an active process maintained by a mutant EGFRinduced cytokine circuit in glioblastoma[J]. Genes Dev, 2010,24(16):1731-1745.
28. Johnson LA, Scholler J,Ohkuri T, et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma[J]. Sci Transl Med, 2015,7(275):275ra22.
29. Goldie JH, Coldman AJ. Amathematicmodel for relating the drug sensitivity of tumors to their spontaneous mutation rate[J]. Cancer Treat Rep, 1979,63(11-12):1727-1733.
30. Goldie JH, Coldman AJ. Quantitative model for multiple levels of drug resistance in clinical tumors[J]. Cancer Treat Rep, 1983,67(10):923-931.
31. Foo J, Michor F. Evolution of acquired resistance to anticancer therapy[J]. J Theor Biol, 2014,355: 10-20.
32. Goffart N, Kroonen J, Rogister B. Glioblastoma-initiating cells: relationship with neural stem cells and the microenvironment[ J]. Cancers Basel), 2013,5(3):1049-1071.
33. Friedmann-Morvinski D, Bhargava V, Gupta S, et al. Identification of therapeutic targets for glioblastoma by network analysis[J]. Oncogene 2015 May 11. doi: 10.1038/ onc.2015.2119. [Epub ahead of print]
34. Zhang X, Zhang W, Mao XG, et al. Targeting role of glioma stem cells for glioblastoma multiforme[J]. Curr Med Chem, 2013,20(15):1974-1984.
35. Olmez I, Shen W, McDonald H, et al. Dedifferentiation of patient-derived glioblastoma multiforme cell lines results in a cancer stem cell-like state with mitogen-independent growth[J]. J Cell Mol Med, 2015,19(6):1262-1272.
36. de Almeida Sassi F, Lunardi Brunetto A, Schwartsmann G, et al. Glioma revisited: from neurogenesis and cancer stem cells to the epigenetic regulation of the niche[J]. J Oncol, 2012,2012: 537861.
37. Wabik A, Jones PH. Switching roles: the functional plasticity of adult tissue stem cells[J]. EMBO J, 2015,34(9):1164-1179.
38. Kim SH, Joshi K, Ezhilarasan R, Myers TR, et al. EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner[J]. Stem Cell Reports, 2015,4(2):226-238.
39. Zhong X, Safa AR. Phosphorylation of RNA helicase A by DNA-dependent protein kinase is indispensable for expression of the MDR1 gene product P-glycoprotein in multidrug-resistant human leukemia cells[J]. Biochemistry, 2007,46(19):5766-5775.
40. Xi G, Hayes E, Lewis R, Ichi S, et al. CD133 and DNA-PK regulateMDR1 via the PI3K- or AktNF-kB pathway in multidrug- resistant glioblastoma cells in vitro[J]. Oncogene 2015 Mar 30. doi: 10.1038/onc.2015.78. [Epub ahead of print]
41. Garner JM, Ellison DW, Finkelstein D, et al. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations[J]. PLoS One, 2015,10(5):e0125838.
42. Mao DD, Gujar AD, Mahlokozera T, et al. A CDC20-APC/ SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells[J]. Cell Rep, 2015,11(11):1809-821.
43. Natsume A, Ito M, Katsushima K, et al. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma[J]. Cancer Res, 2013,73(14):4559-4570.
44. Jackson M, Hassiotou F, Nowak A. Glioblastoma stemlike cells: at the root of tumor recurrence and a therapeutic target[J]. Carcinogenesis, 2015,36(2):177-185.
45. Debus J, Abdollahi A. For the next trick: new discoveries in radiobiology applied to glioblastoma[J]. Am Soc Clin Oncol Educ Book, 2014;e95-9.
46. Booth L, Roberts JL, Conley A, et al. HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells[J]. Cancer Biol Ther, 2014, 15(3):305-316.
47. Chiao MT, Cheng WY, Yang YC, et al. Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells[J]. Autophagy, 2013,10:1509-1526.
48. Friedman MD, Jeevan DS, Tobias M, et al. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid[J]. Oncol Rep, 2013,30(4):1645-1650.
49. Sunayama J, Sato A, Matsuda K, Tachibana K, et al. FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity[J]. Stem Cells, 2011,29(9):1327-1337.
50. Di Cristofori A, Ferrero S, Bertolini I, et al. The vacuolar H+ ATPase is a novel therapeutic target for glioblastoma[J]. Oncotarget, 2015,6(19):17514-17531.
51. Pareja F, Macleod D, Shu C, et al. PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD. Mol Cancer Res, 2014,12(7):987-1001.
52. Karpel-Massler G, Shu C, Chau L, Banu M, et al. Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo[J]. Oncotarget, 2015,6(16):14507-21.
53. Asuthkar S, Velpula KK, Chetty C, et al. Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity[J]. Oncotarget, 2012,3(11):1439-1454.
54. Gao X, Jin W. The emerging role of tumor-suppressive microRNA-218 in targeting glioblastoma stemness[J]. Cancer Lett, 2014,353(1):25-31.
55. Wong HK, Fatimy RE, Onodera C, et al. The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma[J]. Mol Ther, 2015,23(7):1234-1247.
56. Kouri FM, Hurley LA, Daniel WL, et al. miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma[J]. Genes Dev, 2015,29(7):732-745.
57. Chu PM, Ma HI, Chen LH, et al. Deregulated microRNAs identified in isolated glioblastoma stem cells: an overview[J]. Cell Transplant, 2013,22(4):741-753.
58. Bier A, Giladi N, Kronfeld N, et al. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1[J]. Oncotarget, 2013,4(5):665-676.
59. Lee HK, Bier A, Cazacu S, et al. MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor[J]. PLoS One, 2013,8(2):e54652.
60. Yao Y, Ma J, Xue Y, et al. MiR-449a exerts tumor-suppressive functions in human glioblastoma by targeting Myc-associated zinc-finger protein[J]. Mol Oncol, 2015; 9(3):640-656.
61. Fazi F, Blandino G. MicroRNAs: non coding pleiotropic factors in development, cancer prevention and treatment[J]. Microrna, 2013,2(2):81.
62. Ma J, Yao Y, Wang P, et al. MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Krüppel-like factor 4[J]. Cancer Lett, 2014,355(1):85-95.
63. Shang C, Guo Y, Hong Y, et al. MiR-21 up-regulation mediates glioblastoma cancer stem cells apoptosis and proliferation by targeting FASLG[J]. Mol Biol Res, 2015, 42(3):721-727.
64. Rathod SS, Rani SB, Khan M, et al. Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways[J]. FEBS Open Bio, 2014,4: 485-495.
65. González-Gómez P, Saánchez P, et al. MicroRNAs as regulators of neural stem cell-related pathways in glioblastoma multiforme[J]. Mol Neurobiol, 2011,44(3):235-249.
66. Yang CM, Chiba T, Brill B, et al. Expression of the miR- 302/367 cluster in glioblastoma cells suppresses tumorigenic gene expression patterns and abolishes transformation related phenotypes[J]. Int J Cancer, 2015 May 20. doi: 10.1002/ijc.29606. [Epub ahead of print]
67. Liu J,AlbrechtAM,NiX, et al.Glioblastoma tumor initiating cells: therapeutic strategies targeting apoptosis and microRNA pathways[J]. Curr MolMed, 2013,13(3):352-357.
68. Liu Q, Nguyen DH, Dong Q, et al. Molecular properties of CD133+ glioblastoma stem cells derived from treatment- refractory recurrent brain tumors[J]. J Neurooncol, 2009,94(1):1-19.
69. Ruan J, Lou S, Dai Q, et al. Tumor suppressor miR-181c attenuates proliferation, invasion, and self-renewal abilities in glioblastoma[J]. Neuroreport, 2015,26(2):66-73.
70. Tezcan G, Tunca B, Bekar A, et al. MicroRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells[J]. Cell Mol Neurobiol, 2014,34(5): 679-692.
71. Tezcan G, Tunca B, Bekar A, et al. Olea europaea leaf extract improves the treatment response of GBM stem cells by modulating miRNA expression[J]. Am J Cancer Res, 2014,4(5):572-590.
72. Cui JG, Zhao Y, Sethi P, et al. Micro-RNA-128 (miRNA- 128) down-regulation in glioblastoma targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key regulators of brain cell proliferation[J]. J Neurooncol, 2010,98(3):297-304.
73. Godlewski J, Nowicki MO, Bronisz A, et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and selfrenewal[ J]. Cancer Res, 2008,68(22):9125-9130.
74. Peruzzi P, Bronisz A, Nowicki MO, et al. MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells[J]. Neuro Oncol, 2013,15(9):1212-1224.
75. Schonberg DL, Lubelski D, Miller TE, et al. Brain tumor stem cells: Molecular characteristics and their impact on therapy[J]. Mol Aspects Med, 2014,39: 82-101.
76. Nabilsi NH, Deleyrolle LP, Darst RP, et al. Multiplex mapping of chromatin accessibility and DNA methylation within targeted single molecules identifies epigenetic heterogeneity in neural stem cells and glioblastoma[J]. Genome Res, 2014,24(2):329-339.
77. Lopez-Bertoni H, Lal B, Li A, et al. DNMT-dependent suppression of microRNA regulates the induction of GBM tumor-propagating phenotype by Oct4 and Sox2. Oncogene 2014 Oct 20 [Epub ahead of print].
78. Cheng HW, Liang YH, Kuo YL, et al. Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data[J]. Cell Death Dis, 2015 May 7,6:e1753. doi: 10.1038/cddis.2015.77.
79. Zhou J, Patel TR, SirianniRW, et al.Highly penetrative, drugloaded nanocarriers improve treatment of glioblastoma[J]. Proc Natl Acad Sci U S A, 2013,110(29):11751-11756.
80. Kast RE, Boockvar JA, Brüning A, et al. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care[J]. Oncotarget, 2013,4(4):502-530.
81. Jones PA, Baylin SB. The epigenomics of cancer[J]. Cell, 2007,128(4):683-692.
82. Baylin SB, Esteller M, Rountree MR. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer[J]. Hum Mol Genet, 2001,10(7):687-692.
83. Christman JK. 5-Azacytidine and 5-aza-2-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy[J]. Oncogene, 2002 12,21(35):5483-5495.
84. So AY, Jung JW, Lee S, et al. DNA methyltransferase controls stem cell aging by regulating BMI1 and EZH2 through microRNAs[J]. PLoS One, May 10 2011,6(5):e19503.
85. Chang HW, Wang HC, Chen CY. 5-azacytidine induces anoikis, inhibits mammosphere formation and reduces metalloproteinase 9 activity in MCF-7 human breast cancer cells[J]. Molecules, 2014,19(3):3149-3159.
86. Witt O, Deubzer HE,Milde T, et al. HDAC family:What are the cancer relevant targets? Cancer Lett., 2009,277(1):8-21.
87. Alexanian AR, Huang YW. Specific combinations of the chromatin-modifying enzyme modulators significantly attenuate glioblastoma cell proliferation and viability while exerting minimal effect on normal adult stem cells growth[J]. Tumour Biol 2015 Jun 19. [Epub ahead of print]
88. Wongtrakoongate P. Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries[J]. World J Stem Cells, 2015, 7(1):137-148.
89. Connolly R, Stearns V Epigenetics as a therapeutic target in breast cancer[J]. J Mammary Gland Biol Neoplasia, 2012,17(3-4):191-204.
90. Jiang P, Mukthavaram R, Chao Y. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs[J]. J Transl Med, 2014,12:13.
91. Hothi P, Martins TJ, Chen L, et al. High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells[J]. Oncotarget, 2012,3(10):1124-1136.
92. Paranjpe A, Zhang R, Ali-Osman F, et al. Disulfiram is a direct and potent inhibitor of human O6-methylguanine- DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage[J]. Carcinogenesis, 2014,35(3):692-702.
93. Alvarez AA, Field M, Bushnev S, et al. The effects of histone deacetylase inhibitors on glioblastoma-derived stem cells[J]. J Mol Neurosci, 2015,55(1):7-20.
94. Liffers K, Kolbe K, Westphal M, et al . Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIIIOverexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition[J]. Target Oncol 2015 Jun 3. [Epub ahead of print]
95. Dror N, Mandel M, Lavie G. Unique anti-glioblastoma activities of hypericin are at the crossroad of biochemical and epigenetic events and culminate in tumor cell differentiation[J]. PLoS One, 2013;16, 8(9):e73625.
96. Xie Q, Mittal S, Berens ME. Targeting adaptive glioblastoma: an overview of proliferation and invasion[J]. Neuro Oncol, 2014,16(12):1575-1584.